3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Triple Negative Breast Neoplasms
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Osteosarcoma
1
Neoplasms
1
Myelodysplastic Syndromes
1
Mesothelioma, Malignant
1
Mesothelioma
1
Lymphoma, Non-Hodgkin
1
Leukemia, Prolymphocytic, B-Cell
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia, Biphenotypic, Acute
1
Kidney Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Burkitt Lymphoma
1
Interventions
Cyclophosphamide
7
Specimen Handling
5
fludarabine
4
Standard of Care
4
trametinib
3
Practice Guidelines as Topic
3
Magnetic Resonance Spectroscopy
3
GSK2636771
3
Biopsy
3
venetoclax
2
talquetamab
2
osimertinib
2
dabrafenib
2
capivasertib
2
binimetinib
2
X-Rays
2
Thiotepa
2
Tacrolimus
2
Patient Navigation
2
Nivolumab
2
Mycophenolic Acid
2
Methods
2
Mesna
2
Melphalan
2
Filgrastim
2
Educational Status
2
Early Intervention, Educational
2
Crizotinib
2
Ado-Trastuzumab Emtansine
2
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Blood Component Removal
×
30 days
×
Clear all
No trials found.